search
Back to results

Effects of Lutein Supplementation on Subclinical Atherosclerosis

Primary Purpose

Carotid Atherosclerosis, Carotid Intimal Medial Thickness 1

Status
Completed
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Placebo
Lutein group
Combination group
Normal lutein control group
Sponsored by
Peking University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Carotid Atherosclerosis focused on measuring early atherosclerosis, serum lutein, serum lycopene, intima-media thickness, arterial stiffness, combined effect

Eligibility Criteria

45 Years - 68 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • early atherosclerosis;
  • aged 45 to 68 years;
  • Han nationality

Exclusion Criteria:

  • history of myocardial infarction,
  • stroke,
  • revascularization,
  • coronary by-pass operation,
  • local carotid IMT > 1300μm or supplemental vitamin and/or mineral use for ≥ 4 week before the start of the study

Sites / Locations

  • Haidian District

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Placebo Comparator

Experimental

Experimental

Experimental

Arm Label

Placebo

Lutein group

Combination group

Normal lutein control group

Arm Description

early atherosclerosis cases, received starch in hard shell gelatine capsules, once a day

early atherosclerosis cases, received 20mg lutein, once a day

early atherosclerosis cases, received 20mg lutein plus 20mg lycopene, once a day

20mg lutein for subjects free from atherosclerosis, once a day

Outcomes

Primary Outcome Measures

Table 1 Study Specific Characteristic Part One
The percentage of female, race, hypertenion history, diabetes history, and hyperlipemia history was calculated.
Table 1 Study Specific Characteristic of Age
the mean and standard deviation of age was calculated in four groups
Table 1 Study Specific Characteristic of Body Mass Index (BMI)
the mean and standard deviation of BMI in four groups was calculated
Table 1 Study Specific Characteristic of Blood Pressure (BP)
systolic BP and diastolic BP in four groups was measure twice between 15minutes
Table 1 Study Specific Characteristic of Serum Carotenoids
serum major carotenoids, including lutein, zeaxanthin, beta-carotene, and lycopene concentration were measured by hyper-pressure liquid chromatography (HPLC)

Secondary Outcome Measures

Changes of Right Common Carotid Arterial Stiffness Parameter β(R-β) at Baseline and After 12 Months
Arterial stiffness was measured by using a high-resolution B-mode carotid ultrasound with echo-tracking system (Aloka prosound α-10, Aloka Co. Ltd., Tokyo, Japan).
Dietary Intake of Energy During the Study Periods
Dietary intake was assessed at baseline and after 12months by using 3 consecutive 24-hour recalls.
Dietary Intake of Vitamin C,Vitamin E, Lutein Plus Zeaxanthin and Lycopene During the Study Periods
Dietary intake of Vitamin C,Vitamin E, Lutein plus zeaxanthin and Lycopene was assessed at baseline and after 12months by using 3 consecutive 24-hour recalls.

Full Information

First Posted
February 13, 2012
Last Updated
June 18, 2013
Sponsor
Peking University
search

1. Study Identification

Unique Protocol Identification Number
NCT01534533
Brief Title
Effects of Lutein Supplementation on Subclinical Atherosclerosis
Official Title
The Effects of Lutein Supplementation on Subclinical Atherosclerosis
Study Type
Interventional

2. Study Status

Record Verification Date
June 2013
Overall Recruitment Status
Completed
Study Start Date
June 2010 (undefined)
Primary Completion Date
June 2011 (Actual)
Study Completion Date
June 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Peking University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is to investigate the possible positive effects of lutein and lycopene supplementation on early atherosclerosis in Beijing.
Detailed Description
Atherosclerosis is the primary cause of cardiovascular and cerebrovascular diseases, both of which are the top two causes of death in industrialized countries including China. Lutein was found to be protective against atherosclerosis in some case control studies. However, the intervention on atherosclerosis have not been reported. In the present study, 192 subjects were randomly assigned to four groups treated with different amounts of lutein. The investigators observe the changes of serum lutein concentration by hyper-pressure liquid chromatography (HPLC), and compare the differences of common carotid IMT and arterial stiffness by carotid ultrasonography before and after the intervention. Serum biochemistry indexes including cholesterol (CHO), triglyceride (TG), high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C) and glucose (Glu) were measured at 0, 7 and 12 months of treatment by auto-analyzer.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Carotid Atherosclerosis, Carotid Intimal Medial Thickness 1
Keywords
early atherosclerosis, serum lutein, serum lycopene, intima-media thickness, arterial stiffness, combined effect

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
192 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
early atherosclerosis cases, received starch in hard shell gelatine capsules, once a day
Arm Title
Lutein group
Arm Type
Experimental
Arm Description
early atherosclerosis cases, received 20mg lutein, once a day
Arm Title
Combination group
Arm Type
Experimental
Arm Description
early atherosclerosis cases, received 20mg lutein plus 20mg lycopene, once a day
Arm Title
Normal lutein control group
Arm Type
Experimental
Arm Description
20mg lutein for subjects free from atherosclerosis, once a day
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
one gelatine capsule containing starch per day, for 12 months
Intervention Type
Dietary Supplement
Intervention Name(s)
Lutein group
Intervention Description
one gelatine capsule containing 20mg lutein per day, for 12 months
Intervention Type
Dietary Supplement
Intervention Name(s)
Combination group
Intervention Description
one gelatine capsule containing 20mg lutein and 20 mg lycopene per day, for 12 months
Intervention Type
Dietary Supplement
Intervention Name(s)
Normal lutein control group
Intervention Description
subjects without early atherosclerosis, treated with one gelatine capsule containing 20mg lutein per day, for 12 months
Primary Outcome Measure Information:
Title
Table 1 Study Specific Characteristic Part One
Description
The percentage of female, race, hypertenion history, diabetes history, and hyperlipemia history was calculated.
Time Frame
at baseline
Title
Table 1 Study Specific Characteristic of Age
Description
the mean and standard deviation of age was calculated in four groups
Time Frame
at baseline
Title
Table 1 Study Specific Characteristic of Body Mass Index (BMI)
Description
the mean and standard deviation of BMI in four groups was calculated
Time Frame
at baseline
Title
Table 1 Study Specific Characteristic of Blood Pressure (BP)
Description
systolic BP and diastolic BP in four groups was measure twice between 15minutes
Time Frame
at baseline
Title
Table 1 Study Specific Characteristic of Serum Carotenoids
Description
serum major carotenoids, including lutein, zeaxanthin, beta-carotene, and lycopene concentration were measured by hyper-pressure liquid chromatography (HPLC)
Time Frame
at baseline
Secondary Outcome Measure Information:
Title
Changes of Right Common Carotid Arterial Stiffness Parameter β(R-β) at Baseline and After 12 Months
Description
Arterial stiffness was measured by using a high-resolution B-mode carotid ultrasound with echo-tracking system (Aloka prosound α-10, Aloka Co. Ltd., Tokyo, Japan).
Time Frame
at baseline and after 12 months
Title
Dietary Intake of Energy During the Study Periods
Description
Dietary intake was assessed at baseline and after 12months by using 3 consecutive 24-hour recalls.
Time Frame
at baseline and 12 months
Title
Dietary Intake of Vitamin C,Vitamin E, Lutein Plus Zeaxanthin and Lycopene During the Study Periods
Description
Dietary intake of Vitamin C,Vitamin E, Lutein plus zeaxanthin and Lycopene was assessed at baseline and after 12months by using 3 consecutive 24-hour recalls.
Time Frame
at baseline and 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
45 Years
Maximum Age & Unit of Time
68 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: early atherosclerosis; aged 45 to 68 years; Han nationality Exclusion Criteria: history of myocardial infarction, stroke, revascularization, coronary by-pass operation, local carotid IMT > 1300μm or supplemental vitamin and/or mineral use for ≥ 4 week before the start of the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Xiaoming Lin, M.M.
Organizational Affiliation
Peking University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Haidian District
City
Beijing
ZIP/Postal Code
100191
Country
China

12. IPD Sharing Statement

Citations:
PubMed Identifier
21872250
Citation
Zou Z, Xu X, Huang Y, Xiao X, Ma L, Sun T, Dong P, Wang X, Lin X. High serum level of lutein may be protective against early atherosclerosis: the Beijing atherosclerosis study. Atherosclerosis. 2011 Dec;219(2):789-93. doi: 10.1016/j.atherosclerosis.2011.08.006. Epub 2011 Aug 10.
Results Reference
background

Learn more about this trial

Effects of Lutein Supplementation on Subclinical Atherosclerosis

We'll reach out to this number within 24 hrs